荃信生物(02509)涨6.97% 与华东医药共同开展标的产品QX005N临床及非临床研究及注册相关工作

金吾财讯07-23

金吾财讯 | 荃信生物(02509)盘中曾涨超8%，截至发稿，涨6.97%，报21.5港元，成交额186万港元。消息面上，公司发布公告，2024年7月19日，公司与华东医药(000963)的全资附属公司中美华东订立合作协议，就标的产品QX005N共同开展临床及非临床研究及注册相关工作。公告称，若中美华东行使选择权，将承担标的产品在授权地区内的营销及推广，而公司则负责标的产品及临床试验样品的供应及质量控制，标的产品及临床试验样品将由公司的间接非全资附属公司赛孚士生产。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2453653705?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20210810/NjUzMWVjZjQ5MDRjNGY2OWIzOTk1NmJhNzg4ZTIwMmI4MTQyOTUwMDc1MDA=.jpg","is_english":false,"pubTime":"2024-07-23 14:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453653705","market":"us","top_or_hot":-1,"title":"荃信生物(02509)涨6.97% 与华东医药共同开展标的产品QX005N临床及非临床研究及注册相关工作","media":"金吾财讯","content":"<html><body><p>金吾财讯 | 荃信生物(02509)盘中曾涨超8%，截至发稿，涨6.97%，报21.5港元，成交额186万港元。消息面上，公司发布公告，2024年7月19日，公司与<a href=\"https://laohu8.com/S/000963\">华东医药</a>(000963)的全资附属公司中美华东订立合作协议，就标的产品QX005N共同开展临床及非临床研究及注册相关工作。公告称，若中美华东行使选择权，将承担标的产品在授权地区内的营销及推广，而公司则负责标的产品及临床试验样品的供应及质量控制，标的产品及临床试验样品将由公司的间接非全资附属公司赛孚士生产。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荃信生物(02509)涨6.97% 与华东医药共同开展标的产品QX005N临床及非临床研究及注册相关工作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荃信生物(02509)涨6.97% 与华东医药共同开展标的产品QX005N临床及非临床研究及注册相关工作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-23 14:43 北京时间&nbsp;&nbsp;&nbsp;<a href=1940893><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 荃信生物(02509)盘中曾涨超8%，截至发稿，涨6.97%，报21.5港元，成交额186万港元。消息面上，公司发布公告，2024年7月19日，公司与华东医药(000963)的全资附属公司中美华东订立合作协议，就标的产品QX005N共同开展临床及非临床研究及注册相关工作。公告称，若中美华东行使选择权，将承担标的产品在授权地区内的营销及推广，而公司则负责标的产品及临床试验样品的供应及...</p>\n\n<a href=\"1940893\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"1940893","article_id":"2453653705","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210810/NjUzMWVjZjQ5MDRjNGY2OWIzOTk1NmJhNzg4ZTIwMmI4MTQyOTUwMDc1MDA=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453653705","pubTimestamp":1721717005,"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 荃信生物(02509)盘中曾涨超8%，截至发稿，涨6.97%，报21.5港元，成交额186万港元。消息面上，公司发布公告，2024年7月19日，公司与华东医药(000963)的全资附属公司中美华东订立合作协议，就标的产品QX005N共同开展临床及非临床研究及注册相关工作。公告称，若中美华东行使选择权，将承担标的产品在授权地区内的营销及推广，而公司则负责标的产品及临床试验样品的供应及质量控制，标的产品及临床试验样品将由公司的间接非全资附属公司赛孚士生产。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0196":"行业龙头","BK1161":"生物科技","BK0188":"融资融券","000963":"华东医药","BK0175":"白马股","BK0132":"高送转概念","BK0183":"MSCI概念","BK0187":"一线龙头","BK0209":"零售","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","02509":"荃信生物-B"},"translate_title":"Quanxin Biotech (02509) rose 6.97% and jointly carried out clinical and non-clinical research and registration related work of the target product QX005N with Huadong Medicine","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000963":1,"02509":1},"content_text":"金吾财讯 | 荃信生物(02509)盘中曾涨超8%，截至发稿，涨6.97%，报21.5港元，成交额186万港元。消息面上，公司发布公告，2024年7月19日，公司与华东医药(000963)的全资附属公司中美华东订立合作协议，就标的产品QX005N共同开展临床及非临床研究及注册相关工作。公告称，若中美华东行使选择权，将承担标的产品在授权地区内的营销及推广，而公司则负责标的产品及临床试验样品的供应及质量控制，标的产品及临床试验样品将由公司的间接非全资附属公司赛孚士生产。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453653705"}